16th Call for proposals 2018 - Innovative Medicines Initiative 2 Joint Undertaking - H2020-JTI-IMI2 H2020-JTI-IMI2-2018-16-SINGLE-STAGE Closed!
Objectives
The aim of the AMR Accelerator is to progress a pipeline of potential medicines, including but not limited to new antibiotics, to treat patients with resistant bacterial infections in Europe and across the globe or to prevent them.
Specifically, if successful, projects in the Accelerator are expected to deliver up to >10 new preclinical candidates and >5 ‘phase 2-ready’ assets over a roughly six-year period.
The AMR Accelerator will provide, under one operational structure, a wide-ranging series of projects that will address many of the scientific challenges in AMR. The scientific scope will be broad, including prevention (vaccines, mAbs, immunoprophylaxis, other means) and treatment (new antibiotics, non-antibiotic alternatives, and combinations)
Actions
The list of topics covered by this call is:
- IMI2-2018-16-01: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
- IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
- IMI2-2018-16-03: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
- IMI2-2018-16-04: Determination of gepotidacin levels in tonsils and prostatic tissue
- IMI2-2018-16-05: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
- IMI2-2018-16-06: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
- IMI2-2018-16-07: Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
European community funding
The Community provisional funding available for the call for proposals is:
- 46,90 Million EUR (Global Budget)
All the important deadlines
- 24 October 2018 - 3 months ago (Deadline for the presentation of proposals)
Further information about the call
Official webpage of the call
Useful documents
Organisations eligible to participate
Opened to the following bodies or institutes with legal status established in the covered areas:
- Any legal organisation
Covered areas
Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:
- European Union (EU)
Directorate-Generale responsible
Directorate-General for Research
Related calls for proposals
- 17th Call for proposals 2019 - Innovative Medicines Initiative 2 Joint Undertaking - H2020-JTI-IMI2
- Call for proposals 2019 - H2020 - SHIFT2RAIL Joint Undertaking 2019
- Call for proposals 2019 - Fuel Cells and Hydrogen 2 Joint Undertaking (FCH2 JU)
- Call for proposals 2018 - H2020 - SESAR 2020 IR-VLD WAVE 2
- Call for Proposals 2019 - 09 - Clean Sky 2
Explore other programmes
